- 2020 Fourth QuarterRevenues Expected to Increase More Than 28% to
- 2020 Fiscal Year Revenues Expected to Increase Approximately 31% to
Preliminary Fourth Quarter 2020 Revenue:
- Total revenue for the fourth quarter of 2020 is expected to range from
$12.5 million to$12.8 million , reflecting growth of 28% to 31% (and growth of 43% to 46%, excluding a one-time$1 million sale in 2019 toKaiser Permanente ) compared to$9.8 million in the same quarter in 2019.- WatchPAT™ revenue for the fourth quarter of 2020 is expected to range from
$12.0 to$12.3 million , representing growth of 32% to - 35% (and growth of 48% to 52%, excluding a one-time$1 million sale in 2019 toKaiser Permanente ) compared to$9.1 million in the same quarter in 2019. U.S. WatchPAT revenue for the fourth quarter of 2020 is expected to range from$10.0 million to$10.3 million , representing growth of 36% to 40% (and growth of 58% to 63%, excluding a one-time$1 million sale in 2019 toKaiser Permanente ) compared to$7.3 million in the same quarter in 2019.
- WatchPAT™ revenue for the fourth quarter of 2020 is expected to range from
Preliminary Full Year 2020 Revenue:
- Total revenue for the full year ended
December 31, 2020 is expected to range from$40.8 million to$41.1 million, reflecting a growth of approximately 31% (and growth of 35% to36%, excluding a one-time$1 million sale in 2019 toKaiser Permanente ) compared to$31.3 million in 2019.- WatchPAT revenue for the full year ended
December 31, 2020 is expected to range from$38.6 million to$38.9 million , an increase of 33% to 34% (and growth of 38% to 39%, excluding a one-time$1 million sale in 2019 toKaiser Permanente ) compared to$29.0 million in 2019. U.S. WatchPAT revenue for the full year endedDecember 31, 2020 is expected to range from$31.6 million to$31.9 million , reflecting growth of 41% to 42% (and growth of 48% to 49%, excluding a one-time$1 million sale in 2019 toKaiser Permanente ) compared to$22.4 million in 2019.
- WatchPAT revenue for the full year ended
“Following a strong Q3, we were pleased to see that trend continue into the fourth quarter, largely driven by our
These preliminary results are based on management's initial analysis of revenues for the quarter and year ended December 31, 2020 and are subject to further internal review and audit by the Company's external auditors.
The Company plans to report financial results for the fourth quarter and full year ended
About
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other applicable securities laws. Statements preceded by, followed by, or that otherwise include the words "believes", "expects", "anticipates", "intends", "estimates", "plans", and similar expressions or future or conditional verbs such as "will", "should", "would", "may" and "could" are generally forward-looking in nature and not historical facts. For example, when we discuss Itamar Medical’s expected revenue for the quarter and the fiscal year ended
Itamar Medical Investor Relations Contact (
Phone: +1-415-937-5412
investors@itamar-medical.com
2021 GlobeNewswire, Inc., source